Madrigal Pharmaceuticals (MDGL) Stock Price Falls After Q3 Profit Turns Positive

Madrigal Pharmaceuticals just delivered its Q3 2026 scorecard, flipping to a profit while the stock dropped 8.1% to about US$396 in the first trading session after the release. That clash between headlines and price is the story. The company posted US$431.3m in Rezdiffra net sales and logged US$55.4m in net income, the first profitable quarter after a long loss making stretch. Traders marked the share price down. The financials point to a different mood, built around a fast scaling liver disease franchise and a business that is now generating cash instead of burning it.

Love the flip to profitability at Madrigal Pharmaceuticals but concerned about relying on a single fast scaling drug launch for returns? Compare this story against our screener of list of solid balance sheet and fundamentals stocks (23 results) to see how it stacks up on resilience and cash strength.

Q3 2026 Earnings Summary

• Total Revenue (Q3 2026 vs Q3 2025): US$431.3m vs US$287.3m (up about 50%)
• Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): profit of US$55.4m vs loss of US$114.2m (moved into profitability)
• Basic EPS (Q3 2026 vs Q3 2025): US$2.40 per share vs loss of US$5.08 per share (swing to positive earnings per share)
• Active Rezdiffra Patients (Q3 2026 vs Q3 2025): ~55,850 vs ~29,500 (patient count roughly doubled year on year)

Tired of scrolling through paragraphs of earnings commentary and raw figures for Madrigal Pharmaceuticals? See the full financial picture, including how the balance sheet now looks, in our visual company report for Madrigal Pharmaceuticals.

Evaluating Madrigal’s Rezdiffra Growth Milestones

The bullish story on Madrigal Pharmaceuticals hinges on whether Rezdiffra can move from an early launch to a long lived growth engine.

"The main thing that has to go right is that Madrigal contains rising SG&A and R&D spending and manages increasing gross-to-net discounts while continuing to convert a very underpenetrated MASH specialty pool into long-term Rezdiffra users and future combination-therapy candidates."

Q3 shows real progress on that checklist. Active Rezdiffra patients roughly doubled year on year while net sales reached US$431.3m and trailing twelve month revenue hit about US$1.3b. At the same time, Madrigal delivered its first quarterly profit and has now generated positive operating cash flow for two straight quarters, early evidence that commercial scale is starting to offset heavy SG&A and R&D outlays even as gross to net stays in the mid to high 30% range.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Madrigal Bear Case: Costs Ease, Discounts Still Bite

The skeptical view argues Madrigal Pharmaceuticals could stay loss making as Rezdiffra discounts and operating expenses climb.

"Bearish analysts expect Madrigal Pharmaceuticals to remain heavily exposed to a single commercial asset in Rezdiffra, while rising SG&A and R&D, including higher gross-to-net discounts, keep the business loss making."

Q3 cuts directly against the perpetual loss claim. Madrigal posted US$55.4m in net income and positive operating cash flow, helped by R&D that was lower than the prior year. The ceiling moves rather than disappears. Gross to net sits in the mid to high 30% range, with management flagging a shift toward the high end in 2027 and no ex U.S. offset yet, which supports the concern on pricing pressure even as profitability appears achievable.

Hunt For Quiet Fundamental Shifts

Madrigal Pharmaceuticals shows that earnings momentum and share prices can diverge sharply. The real opportunity is identifying stocks that may be undervalued before the broader market recognises their potential.

• Company 1 - 28% below our estimate - converts rising digital engagement and underpenetrated credit demand into fee-based services and higher-margin lending.
• Company 2 - 30% below our estimate - links subscription software usage to data centre capacity so incremental workloads scale through existing cloud relationships.
• Company 3 - 33% below our estimate - sells GPU platforms that AI-focused data centres standardise on as power constraints and rival ecosystems adjust.

Three companies from the same screener. Open every one of the 35 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com